4-82-725
26.2
[]. A G Fragkaki, et al. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS. J Mass Spectrom. 25 May;5(5):74-8.
[2]. Ebru U?aktürk, et al. Development of Sensitive and Specific Analysis of Vildagliptin in Pharmaceutical Formulation by Gas Chromatography-Mass Spectrometry. J Anal Methods Chem. 25:25:7744.
[3]. Eung Ju Kim, et al. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS One. 24 Jun 5;9(6):e9784.
[4]. Josep Marcos, et al. Urinary cysteinyl progestogens: Occurrence and origin. J Steroid Biochem Mol Biol. 25 Aug:52:53-6.
[5]. Lore Geldof, et al. Metabolism of methylstenbolone studied with human liver microsomes and the uPA?/?-SCID chimeric mouse model. Biomed Chromatogr. 24 Jul;28(7):974-85.
H32-H35-H39-H335
P26-P264-P27-P27-P28-P32+P352-P34+P34-P35+P35+P338-P33-P362+P364-P43+P233-P45-P5
GHS7
沪ICP备79645号
